Clinical study to investigate safety and efficacy on a combined use of rituximab and auto-gamma/delta T cell therapy for CD20-positive B-cell lymphoma.

Clinical study to investigate safety and efficacy on a combined use of rituximab and auto-gamma/delta T cell therapy for CD20-positive B-cell lymphoma. - Clinical study to investigate safety and efficacy on a combined use of rituximab and auto-gamma/delta T cell therapy for CD20-positive B-cell lymphoma.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003641

Enrollment

Registered

2010-05-19

Start date

2010-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CD20-positive B-cell lymphoma

Interventions

Patients receive auto-gamma/delta T cell therapy (day1) and rituximab (day8) every 2 weeks. This treatment repeats 6 courses.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: B-cell lymphoma patients who meet the following: - CD20-positive; - Performance status is 0-1; - No serious abnormality in heart, lung, bone marrow, liver, and renal functions.

Exclusion criteria

Exclusion criteria: Patients who have: - Active enteritis; - Active autoimmune diseases; - Active infections; - Other cancers; - Other serious complications; - Continuous systemic administration of steroids.

Design outcomes

Primary

Measure	Time frame
Safety : Adverse events	—

Secondary

Measure	Time frame
Overall survival Event free survival Response of measurable lesion Immunological responses	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026